Current Approaches to Skin Cancer Management in Organ Transplant Recipients

Seminars in Cutaneous Medicine and Surgery

Volumn 30, Issue 1, 2011, Pages 35-47

  Singh, Meena K ^a   Brewer, Jerry D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; EVEROLIMUS; FLUOROURACIL; IMIQUIMOD; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; RESIQUIMOD; RETINOID;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CARCINOGENESIS; CHEILITIS; CHEMORADIOTHERAPY; CHEMOSURGERY; CRYOTHERAPY; DRUG POTENCY; GRAFT RECIPIENT; HEADACHE; HEALTH EDUCATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; IMMUNE DEFICIENCY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; MERKEL CELL TUMOR; NONMELANOMA SKIN CANCER; ORGAN TRANSPLANTATION; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRECANCER; RASH; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA; UNITED STATES;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOCOMPROMISED HOST; MELANOMA; RISK FACTORS; SKIN NEOPLASMS; TRANSPLANTATION IMMUNOLOGY;

EID: 79955431214     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2011.02.003     Document Type: Review

References (105)

1. Rogers H.W., Weinstock M.A., Harris A.R., et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010, 283-287.
2. Cancer Facts and Figures 2009 2009, American Cancer Society, American Cancer Society, Atlanta.
3. Hartevelt M.M., Bavinck J.N., Kootte A.M., et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990, 49:506-509.
4. Penn I. Post-transplant malignancy: The role of immunosuppression. Drug Saf 2000, 23:101-113.
5. English D.R., Armstrong B.K., Kricker A., et al. Sunlight and cancer. Cancer Causes Control 1997, 8:271-283.
6. Halliday G.M. Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat Res 2005, 571:107-120.
7. Kripke M.L. Ultraviolet radiation and immunology: Something new under the sun-Presidential address. Cancer Res 1994, 54:6102-6105.
8. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534.
9. Kelly G.E., Meikle W., Sheil A.G. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987, 44:429-434.
10. Jensen P., Hansen S., Moller B., et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999, 40:177-186.
11. O'Connor D.P., Kay E.W., Leader M., et al. Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: Correlation with human papillomaviruses?. Diagn Mol Pathol 2001, 10:190-199.
12. Stockfleth E., Nindl I., Sterry W., et al. Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg 2004, 30:604-609.
13. Bennett M.A., O'Grady A., Kay E.W., et al. p53 mutations in squamous cell carcinomas from renal transplant recipients. Biochem Soc Trans 1997, 25:342-345.
14. Bouwes-Bavinck J.N., Hardie D.R., Green A., et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996, 61:715-721.
15. Grabbe S., Granstein R.D. Mechanisms of ultraviolet radiation carcinogenesis. Chem Immunol 1994, 58:291-313.
16. Mithoefer A.B., Supran S., Freeman R.B. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transplant 2002, 8:939-944.
17. Danpanich E., Kasiske B.L. Risk factors for cancer in renal transplant recipients. Transplantation 1999, 68:1859-1864.
18. Penn I. Neoplastic complications of transplantation. Semin Respir Infect 1993, 8:233-239.
19. Ramsay H.M., Fryer A.A., Reece S., et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000, 36:167-176.
20. Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am 1993, 7:431-445.
21. Ferrandiz C., Fuente M.J., Ribera M., et al. Epidermal dysplasia and neoplasia in kidney transplant recipients. J Am Acad Dermatol 1995, 33:590-596.
22. Liddington M., Richardson A.J., Higgins R.M., et al. Skin cancer in renal transplant recipients. Br J Surg 1989, 76:1002-1005.
23. Taylor A.E., Shuster S. Skin cancer after renal transplantation: The causal role of azathioprine. Acta Dermatol Venereol 1992, 72:115-119.
24. Jensen P., Hansen S., Moller B., et al. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone?. Transplant Proc 1999, 31:1120.
25. Dantal J., Hourmant M., Cantarovich D., et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 1998, 351:623-628.
26. Ducloux D., Carron P.L., Rebibou J.M., et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998, 65:1270-1272.
27. Shamanin V., zur Hausen H., Lavergne D., et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996, 88:802-811.
28. Leigh I.M., Buchanan J.A., Harwood C.A., et al. Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. J Acquir Immune Defic Syndr 1999, 21(suppl 1):S49-S57.
29. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000, 7:147-156.
30. Lindelof B., Sigurgeirsson B., Gabel H., et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000, 143:513-519.
31. Veness M.J., Quinn D.I., Ong C.S., et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: The Australian experience. Cancer 1999, 85:1758-1764.
32. Martinez J.C., Otley C.C., Stasko T., et al. Transplant-Skin Cancer Collaborative: Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003, 139:301-306.
33. Ong C.S., Keogh A.M., Kossard S., et al. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999, 40:27-34.
34. Matin R.N., Mesher D., Proby C.M., et al. Skin Care in Organ Transplant patients, Europe (SCOPE) group: Melanoma in organ transplant recipients: Clinicopathological features and outcome in 100 cases. Am J Transplant 2008, 8:1891-1900.
35. Stasko T., Brown M.D., Carucci J.A., et al. International Transplant-Skin Cancer Collaborative; European Skin Care in Organ Transplant Patients Network: Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004, 30:642-650.
36. Berg D., Otley C.C. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002, 47:1-17.
37. Stockfleth E., Ulrich C., Meyer T., et al. Epithelial malignancies in organ transplant patients: Clinical presentation and new methods of treatment. Recent Results Cancer Res 2002, 160:251-258.
38. Dragieva G., Prinz B.M., Hafner J., et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004, 151:196-200.
39. Pearlman D.L. Weekly pulse dosing: Effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991, 25:665-667.
40. Mann M., Berk D.R., Petersen J. Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. J Drugs Dermatol 2008, 7:685-688.
41. Ulrich C., Bichel J., Euvrard S., et al. Topical immunomodulation under systemic immunosuppression: Results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007, 157(suppl 2):25-31.
42. Brown V.L., Atkins C.L., Ghali L., et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: Randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005, 141:985-993.
43. Piaserico S., Belloni-Fortina A., Rigotti P., et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007, 39:1847-1850.
44. Halliday G.M., Dickinson J.L., Muller H.K. Retinoic acid protects Langerhans' cells from the effects of the tumour promotor 12-O-tetradecanoylphorbol 13-acetate. Immunology 1989, 67:298-302.
45. Euvrard S., Verschoore M., Touraine J.L., et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992, 340:48-49.
46. Chen K., Craig J.C., Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: A systematic review of randomized controlled trials. Br J Dermatol 2005, 152:518-523.
47. Kraemer K.H., DiGiovanna J.J., Peck G.L. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992, 19:715-718.
48. De Graaf Y.G., Euvrard S., Bouwes-Bavinck J.N. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 2004, 30:656-661.
49. Kraemer K.H., DiGiovanna J.J., Moshell A.N., et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988, 318:1633-1637.
50. Smit J.V., de Sevaux R.G., Blokx W.A., et al. Acitretin treatment in (pre) malignant skin disorders of renal transplant recipients: Histologic and immunohistochemical effects. J Am Acad Dermatol 2004, 50:189-196.
51. Kovach B.T., Sams H.H., Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transpl 2005, 19:726-734.
52. Kuflik E.G. Cryosurgery for skin cancer: 30-Year experience and cure rates. Dermatol Surg 2004, 30:297-300.
53. Kopf A.W., Bart R.S., Schrager D., et al. Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol 1977, 113:439-443.
54. Neville J.A., Welch E., Leffell D.J. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007, 4:462-469.
55. Mertz K.D., Proske D., Kettelhack N., et al. Basal cell carcinoma in a series of renal transplant recipients: Epidemiology and clinicopathologic features. Int J Dermatol 2010, 49:385-389.
56. Sterry W., Ruzicka T., Herrera E., et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002, 147:1227-1236.
57. Vidal D., Matias-Guiu X., Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 2004, 29:518-525.
58. Clayton A.S., Stasko T. Treatment of nonmelanoma skin cancer in organ transplant recipients: Review of responses to a survey. J Am Acad Dermatol 2003, 49:413-416.
59. Tucker S.B., Polasek J.W., Perri A.J., et al. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol 2006, 54:1033-1038.
60. Stenquist B., Wennberg A.M., Gisslen H., et al. Treatment of aggressive basal cell carcinoma with intralesional interferon: Evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 1992, 27:65-69.
61. Mohs F.E. Chemosurgery: Microscopically controlled surgery for skin cancer-Past, present and future. J Dermatol Surg Oncol 1978, 4:41-54.
62. Robins P. Chemosurgery: My 15 years of experience. J Dermatol Surg Oncol 1981, 7:779-789.
63. Locke J., Karimpour S., Young G., et al. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys 2001, 51:748-755.
64. Von Hoff D.D., LoRusso P.M., Rudin C.M., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361:1164-1172.
65. Miller S.J. The National Comprehensive Cancer Network (NCCN) guidelines of care for nonmelanoma skin cancers. Dermatol Surg 2000, 26:289-292.
66. Brantsch K.D., Meisner C., Schonfisch B., et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: A prospective study. Lancet Oncol 2008, 9:713-720.
67. Graham G.F., Clark L.C. Statistical analysis in cryosurgery of skin cancer. Clin Dermatol 1990, 8:101-107.
68. Freeman R.G., Knox J.M., Heaton C.L. The treatment of skin cancer: A statistical study of 1,341 skin tumors comparing results obtained with irradiation, surgery, and curettage followed by electrodesiccation. Cancer 1964, 17:535-538.
69. Love W.E., Bernhard J.D., Bordeaux J.S. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: A systematic review. Arch Dermatol 2009, 145:1431-1438.
70. Brodland D.G., Zitelli J.A. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992, 27:241-248.
71. Rowe D.E., Carroll R.J., Day C.L. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: Implications for treatment modality selection. J Am Acad Dermatol 1992, 26:976-990.
72. Huang C.C., Boyce S.M. Surgical margins of excision for basal cell carcinoma and squamous cell carcinoma. Semin Cutan Med Surg 2004, 23:167-173.
73. El-Sayed S., Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. J Clin Oncol 1996, 14:838-847.
74. Laramore G.E., Scott C.B., al-Sarraf M., et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 1992, 23:705-713.
75. Bachaud J.M., Cohen-Jonathan E., Alzieu C., et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996, 36:999-1004.
76. Jacobs C., Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contracts Program. J Clin Oncol 1990, 8:838-847.
77. Toll A., Salgado R., Yebenes M., et al. Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol 2010, 19:151-153.
78. Cripps C., Winquist E., Devries M.C., et al. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 2010, 17:37-48.
79. Veness M.J., Palme C.E., Morgan G.J. High-risk cutaneous squamous cell carcinoma of the head and neck: Results from 266 treated patients with metastatic lymph node disease. Cancer 2006, 106:2389-2396.
80. Jirakulaporn T., Mathew J., Lindgren B.R., et al. Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol 2009, 27(suppl):1519.
81. Szeimies R.M., Bichel J., Ortonne J.P., et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008, 159:205-210.
82. Otley C.C., Berg D., Ulrich C., et al. Reduction of Immunosuppression Task Force of the International Transplant Skin Cancer Collaborative and the Skin Care in Organ Transplant Patients Europe: Reduction of immunosuppression for transplant-associated skin cancer: Expert consensus survey. Br J Dermatol 2006, 154:395-400.
83. Kahan B.D., Knight R., Schoenberg L., et al. Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience. Transplant Proc 2003, 35(3 suppl):25S-34S.
84. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883-889.
85. Mathew T., Kreis H., Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transpl 2004, 18:446-449.
86. Colegio O.R., Proby C.M., Bordeaux J.S., et al. Prognosis of pretransplant melanoma. Am J Transplant 2009, 9:862. International Transplant Skin Cancer Collaborative (ITSCC), Skin Care in Organ Transplant patients, Europe (SCOPE)Skin Care in Organ Transplant patients, Europe (SCOPE).
87. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996, 61:274-278.
88. Leibovitch I., Huilgol S.C., Selva D., et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia: II Perineural invasion. J Am Acad Dermatol 2005, 53:261-266.
89. Jambusaria-Pahlajani A., Miller C.J., Quon H., et al. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: A systematic review of outcomes. Dermatol Surg 2009, 35:574-585.
90. Carucci J.A., Martinez J.C., Zeitouni N.C., et al. In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: Clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg 2004, 30:651-655.
91. Kowalski L.P., Carvalho A.L. Natural history of untreated head and neck cancer. Eur J Cancer 2000, 36:1032-1037.
92. Veness M.J., Morgan G.J., Palme C.E., et al. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: Combined treatment should be considered best practice. Laryngoscope 2005, 115:870-875.
93. Morton R.P., Rugman F., Dorman E.B., et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985, 15:283-289.
94. Browman G.P. Evidence-based recommendations against neoadjuvant chemotherapy for routine management of patients with squamous cell head and neck cancer. Cancer Invest 1994, 12:662-670.
95. Munro A.J. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995, 71:83-91.
96. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355:949-955. MACH-NC Collaborative Group.
97. Forastiere A.A. Randomized trials of induction chemotherapy: A critical review. Hematol/Oncol Clin North Am 1991, 5:725-736.
98. Martinez J.C., Otley C.C., Okuno S.H., et al. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: Theoretical and practical considerations. Dermatol Surg 2004, 30:679-686.
99. Vokes E.E., Haraf D.J., Kies M.S. The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin Oncol 2000, 27(suppl 8):34-38.
100. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 1998, 16:1318-1324.
101. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998, 338:1798-1804.
102. Adelstein D.J., Lavertu P., Saxton J.P., et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000, 88:876-883.
103. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000, 18:1458-1464.
104. Denis F., Garaud P., Bardet E., et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003, 55:93-98.
105. Dufresne R.G., Curlin M.U. Actinic cheilitis: A treatment review. Dermatol Surg 1997, 23:15-21.